• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    7-Acylamino-9a-methoxymitosanes having enhanced capacity to inhibit animal tumors in vivo relative to mitomycin C are produced by N7-acylation of 7-amino-9a-methoxymitosane, or N1a,N7-diacylation thereof. Carboxamide, thiocarboxamide, urea, thiourea, urethane, thiophosphoramide, phosphoramide, and sulfonamide derivatives are disclosed.
    公开号:SU1364239A3
    申请号:SU843826167
    申请日:1984-12-21
    公开日:1987-12-30
    发明作者:Канеко Такуси；Ши Лай Вонг Генри；Вильям Дойл Терренс
    申请人:Бристоль-Мейерз Компани (Фирма)；
    IPC主号:
    专利说明:

    1 1364239
    This invention relates to the preparation of new derivatives of mitomycin C, namely, 7-acylamino-9a-methoxymitosan of the general formula
    ABOUT
    to
    about
    Z xJl xCHzOCNHa
    l-rtj- -.VT
    ™ "NRi
    ABOUT
    where R is hydrogen or methyl
    Rj means groups, R NHCO-, (R40), PS or, - where Rj is hydrogen, unsubstituted lower alkyl or substituted by fluorine or chlorine, phenyl, benzyl or cyclohexyl, R4 lower alkyl or benzyl with antitumor property.
    The aim of the invention is to develop, on the basis of known methods, a method for the preparation of new compounds with increased pharmacological activity with low toxicity. .
    Etc. and measure 1. 7-formylamino-9a-methoxy-timitosan (BL-6859).
    Under an argon atmosphere, 6 ml of dimethylformamide are added to a mixture of 549 mg (1.78 mmol) of mitomycin C and 214 mg of a 60% dispersion in NaH oil (4.45 mmol). After stirring for 10 minutes at room temperature, the mixture is cooled to -20 ° C and 0.6 ml of phenylformate containing 65% pure product (3.5 mmol) is added. The reaction mixture is stirred for half an hour at which then the tagging is reduced to room temperature for one hour. After stopping the reaction by adding solid COj, the reaction mixture is diluted with ethyl acetate (EtOAc). The resulting precipitate was separated by filtration and the solvent was removed under reduced pressure. The residue is chromatographed on 5% methanol (MeOH) as silica gel to obtain 306 mg (47%) of the title compound, a portion of the KoTopofo is recrystallized from acetone and ether, m.p. 280 C,
    Calculated,%: C 53.04; H 5.01; N 15.46,
    , gN, Oi
    Found,%: C 52.75; H 5.09i N 15.96.
    0
    five
    0
    five
    49, U N 4.43j
    By replacing the phenylformate with a phenylthioacetate or ethylthioformate, 7- (thioacetyl or thioformyl) -amino-9a-methoxy-timitosans can be obtained.
    Example 2. 7-Trifluoroacetyl-amino-9a-methoxymitosan ().
    Based on 300 mg (0.899 mmol), mitomycin and 2.25 mmol NaH, the reaction is carried out as described in Example 1. P-nitrophenyl trifluoroacetate is used as the acylating agent. those on silica gel (10% MeOH-CHjCl ;;) gave 91 mg (24%) of the desired substance as a purple-red amorphous solid with mp. 93-95 S.
    Calculated,%: C 47.45; H 3.98j N 13.01.
    CnH, 7N40i Found,%: С
    N 12.91.
    Example 3. 7-Atstsh1amino-9a-methoxymitosan (BL-6905).
    Based on 668 mg (2 mmol) of mitomycin C and 4 mmol of NaH, the reaction was carried out as indicated in Example 1. 314 mg (2 mmol) of acetic acid N-hydroxysuccinimide ester were used as acylating agents. Replacement chromatography on silica gel ( 3% MeOH-CH Cl, j,) obtained 200 mg (27%) of the title compound with a mp of 110-112 ° C. . Calculated,%: C, 51.77; H 5.62;
    14.21.
    With „Н5оК404-Н-20
    Found,%; C, 51.58; H 5.25 N 14.1.
    Example 4. 7-2-Chloroacetylamino-0 no-9a-methoxymitosan (BL-6904).
    Based on 668 mg (2 mmol) of mitomycin C and 4 mmol of NaH, the reaction is carried out as indicated in Example 1. As an acylating agent, 520 mg (3 mmol) of phenyl chloroacetate are used. Chromatography on silica gel (5% MeOH-CH, jCl,) gave 60 mg (7.3%) of the title compound with mp. 118-120 ° C.
    5 N
    It was also allocated about 100 mg of the original product.
    Calculated,%: C 49.7; H 4.66, N 13.64.
    C, H, gCl,
    Found,%: C 51.31i H 5.05-, N 11.75,
    P. example 5. 7-Methanesulfonyl-amino-9a-methoxymitosan (BL-6885).
    Under an argon atmosphere, 6 ml of dimes pformamide are added to a mixture of 668 mg (2 mmol) and 4 mmol of NaH. After stirring for 20 minutes at room temperature, the mixture is cooled to -25 ° C and 454 mg (2 mmol) of p-nitrophenylmethanesulfonate is added to it. The reaction mixture is held at -25 ° C for 4 hours. After solid CO was added to the reaction mixture, EtOAc was added to it and washed with brine. Drying and removing the solvent gives a purplish red residue, which is chromatographed on neutral alumina (3% MeOH-CH C) to obtain 100 mg (12%) of the title compound, m.p. 126-128 C.
    Vyisleno,%: C 43.14j H 4.75,
    N 12.58.
    C ,, H ,, N Og-HjO
    Found,%: C 42.99; H 4.67, - N 12.6.
    Example 6. (tert.-Butoc rbonylamino) propionyl1 amino-9a-methoxymitosan.
    Based on 350 mg (1.05 mmol) of mitomycin C and 2.62 mmol of NaH, the reaction is carried out as indicated in Example 1. As the acylating agent, the N-hydroxysuccinimide ester M-BOC- / 3- alanine. TLC by chromatographic chromatography (10% CHjOH-CH Clj) gave 181 mg (34%) of the title compound with a mp. 121-125. WITH
    Calculated,%: C, 52.76; H, 6.33; N 13.28.
    Cj, Hj, NjOg-H20
    Found,%: C 52.85; H 6.22; N 12.83.
    Example 7. 7-Methoxycarbonylamino-9a-m-auto-ximitosan (VMU-25069).
    To a mixture of 334 mg (1 mmol) of mitomycin C and 96. Mg (2 mmol) of NaH in the form of a 50% dispersion in oil are added under an atmosphere of N 5 mp dry dimethylformamide (DMF). The mixture is stirred at 10 μm at room temperature, after which it is cooled down to -30 ° C. In solid form, 4.82 mg (2.3 mmol) of methyl p-nitrobenzyl carbonate are added and stirring is continued for 1 hour at. A small amount of solid carbon dioxide (dry ice) is added to the reaction mixture, followed by water and EtOAc. The organic layer is washed with brine and dried over. The residue obtained after evaporation of the solvent is chromatographed on SiOi (2% CHjOH-CHjClj) to give 150 mg (38%) of the desired compound, m.p. 106-107 s.
    Calculated,%: C 52.04; H 5.14; N 14.28,
    C.,
    Found,%: C 52.03; H 5.15; N 14.2.
    Example 8. 7-Ethoxy. Dicarbonyl amino-9a-methoxymitosan (VMU 25082).
    Based on 334 mg (1 mmol) of mitomycin C, 96 mg of a 50% dispersion in mgGsle (2 mmol) of NaH and 450 mg of ethyl p-nitrobenzyl carbonate, the title compound was obtained, in a similar manner to Example 7, in an amount of 150 mg (37 %), mp. SO- 102 ° C ..
    Calculated,%: C 51.55; H 5.64; N 13.34.
    , 75
    Found,%: C 51.52; H 5.64; N 13.47.
    Example 9. 7- (2-Metoxy-etoxy) carboxyl amino-9a-methoxy-timid (VMU-23071).
    . On the basis of 688 mg (2 mmol) of mygomycin C, 192 mg of NaH in the form of a 50% dispersion in oil and 960 mg (4 mmol) of 2-methoxy-t-p-nitrobenzylcarbonate, the desired compound was obtained in the same way as described in Example 7, in the amount of 300 mg (35%), t.Sh1.82- 84 ° C.
    Calculated,%: C, 51.76; H 5.6; N 12.71.
    25
    Found,%: C 52.09-, H 5.5; N 12.72.
    Example 10. 7-Isopropylaminocarbonylamino-9a-methoxymitosan
    (VMU-25003),
    To a mixture of 668 mg (2 mmol), mitomycin at C, 192 mg (4 mmol) of NaH in the form of a 50% dispersion in oil are added to N2 8 ml of dry day. The resulting solution is stirred for 20 minutes at room temperature, after which oh-. 340 mg (4 mmol) of isopropyl isocyanate are added and stirring is continued for another 1 hour. A small amount of dry ice is added to the reaction mixture, then EtOAc and water. The organic layer is washed with brine and dried over Na2S0. The residue obtained after evaporation of the solvent is chromatographed on
    SiO, (3% SNZON-CH, C12) to give 140 mg (17%) of the title compound, so pl. 163-165 ° C.
    Calculated,%: C 52.71; H 5.99; N 16,17 .-
    C, 3Hj, N50, 0.75 HiO
    Found,%: C 53.01; H 6.03; N 15.86.
    Earlier, an eluting fraction gave 120 mg of 1a-isopropylaminocarbon-7- (isopropylaminocarbonsh1) amino-9a-methoxy-timitosan (24%) in an amount of 120 mg.
    Example 11. 7-Cyclohex1-aminocarbonylamino-9a-methoxymitosan (VMU-6936).
    Based on 334 mg (1 mmol) of mitomycin C, 96 mg (2 mmol) of NaH as a 50% dispersion in oil, and 250 mg (2 mmol) of cyclohexyl isoacetate in an amount of 100 mg (22%), the desired compound was obtained by a method described in example 10, so pl, 138-140 ° C. Calculated,%: C 55.86; H 6.5 - N 14.81 fO, 75
    Found: C 55.83, H 6.22, N 14.44
    Previously washed out, the fraction gave 70 mg (14%) of 1a-cyclohexyl-aminocarbonyl-7-cyclohexylaminocarbonylamino-9a-me1 oxymitosan.
     Example 12, 7-Benzylaminocar bonil-9a-methoxymitosan (BL-6955),
    Based on 668 mg (2 mmol) mitomycin C, 192 mg (4 mmol) NaH as a 50% dispersion and 536 mg (4. mmol) of benzyl isocyanate, 110 mg (12%) of the desired compound was obtained by the method described in example 10, mp. 145-1474.
    Calculated,%: C 58.53; H 5.45, N 14.84,
    C jHjsNsOfe
    Found,%: C 58.93; H 5.45; N 14.12,
    Example 13, 7-Cyclopropane Bonil№1no-9a-methoxymitito (BL- 6906),
    Based on 668 mg (2 mmol) of mitomycin C, 4 mmol of NaH and 370 mg (2 mmol (2 mmol) of cyclopropanecarboxylic acid N-hydroxysuccinimide ester), the reaction was carried out as described in Example 1 by chromatography on silica gel (2% CH OH-CHjClj) gives 65 mg (8%) of the desired compound, mp 102-104 ° C,
    Calculated,%: C 55; H 5.59; N 13,5
    C 19H2iN O4, -0.75 HjO
    five
    d
    Q g
    five
    Found,%: C 55,16; H 5.88; N 12.86,
    Example 14, 7-Diethylthiophosphoryl-9a-methoxymitosan (BL-6938),
    Based on 450 ml (1.35 mmol) of mitomycin C, 2.7 mmol of NaH and 280 mg (1.49 mmol) of diethylphosphoryl chloride, the reaction was carried out as described in Example 1. Column chromatography on silica gel (2%) with subsequent silica gel TLC gives 39 mg (8%) of 1a-dieth1-thiophosphoryl-7-dizethylethylthiophosphoryl-amino-9a-methoxymititane (BL-6934), mp, 47-49 C,
    Calculated,%: C 43.26; H 5.68; N 8.77,
     C, zNz H405R252
    Found,%: C 43.29; H 5.41; N 8.83,
    The more polar fraction yielded 91 mg (14%) of the title compound, m.p., 76-79 ° C.
    Calculated,%: C 46,91; H 5.6; N 11.52.
    CI ,, O, PS
    Found,%: C, 47.02; H 5.53, N 11.88.
    Example 15, N-Benzyloxy carbonyl-7-benzyloxycarbonylamino-9a-methoxy-timosan (VMU-25072),
    Based on 668 mg (2 mmol) of mitomycin C, 4 mmol of NaH and 997 mg (4 mmol) of benzyl-N-hydroxy hydroxycarbonate, the reaction is carried out in accordance with Example 7. Chromatography on a Slichagel (2% CHjOH-CH Cl ) received 490 mg (41%) of the title compound, m.p. 68-70 C .:
    . Calculated,%: C, 61.79; H 5.24 N 9.63.
    C3, H ,, N40s
    Found,%: C 61.68; H 5.02; N
    Example 16, 7-Acetylamino-9a-methoxy-1a-methylmitosan (BL-6916).
    Based on 348 g (1 mmol) of porphyromycin, 2 schol NaH and 314 g (2 mmol) of the N-hydroxysuccinimide ester of acetic acid, are carried out according to Example 1. Preparatively TLC on silica gel jCl) receive 40 mg (10%) of the title compound, m.p. 101-103 ° C.
    Calculated,%: C 54.13; H 5.8, N 13.72.
    C, jH, j, (, - 0.5
    N
    Found,%: C 54.37, H 5.71, 13.88.
    Example 17. 7-GZ- (Ethoxycar Borschl) propionyl amino-9a-methoxymi-tozan (BL-6920) „
    Based on 334 mg (1 mmol) of IVIHTO-mycin C, 2 mmol of NaH and 486 mg (2 mmol) of the N-hydroxysuccinimide ester of monoethyl succinate are reacted according to Example 1, by chromatography on alumina (2% CHjOH-CH-jClp, 130 mg (30%) of the title compound, mp 52-55 s.
    Calculated,%: C 52.61; H 6.19; 12.51.
     . 0.75
    Found,%: C 53.99 N 5.69; 12.12.
    Example 18: 7-Benzosch1amino-9a-methoxymitosan (BL-6930).
    Based on 668 mg (2 mmol) of cite C mitom, 4 mmol of NaH and 730 mg (3 mmol) of p-nitrophenyl benzoate, the corresponding reaction was performed as Example 1. 150 mg was obtained by chromatography on alumina (2% CH OH – CH C) %) of the desired compound, m.p. 129-130 ° C.
    Calculated,%: C 57.89; H 5.29; 12.27.
    N
    N
    N
    .
    Found,%: C 575.71; H 5.29; N 12.27.
    Example 19. 7- (2-Chloroethyl-amino) carbonyl-amino-9a-methoxy-tozan (BL-6931).
    Based on 334 mg (1 mmol) of mitomycin C, 2 mmol of NaH and 211 mg (2 mmol) of 2-chloroethyl isocyanate were reacted according to Example 10. 50 mg (11%) of the title compound, m.p. 118-120 0.
    Calculated,%: C 48.16; H 5.16 N 15.6.
    C gHj2CIN50 V0,5- HjO
    Found,% J C 48.21 ,, H 5.16; N15.27.
    The compounds obtained have a higher antitumor activity and relatively low toxicity compared with mitomycin Cj. Of these, 7-formylamino 9a-methoxymitosan (example 1), 7-acetylamino-9a-methoxytimitosan (example 3), and 7-cycle are most preferred.
    five
    0
    lopropancarbonylamino-9a-methoxy-imitosan (Example 13).
    Activity against mouse leukemia P-388.
    Table 1 contains the results of laboratory tests on female females with CDF glands, which were implanted intraperitoneally with a tumor by grafting 10 cells of serous fluid of P-388 pulmonary leukemia and which were then treated with various doses of either the proposed compound or mitomycin C. The compounds were injected intraperitoneally. Each dosage was tested on a group of six smaller ones; on the day of vaccination, they were injected with the compound in a single dosage. In each series of experiments, a group of 10 mice was included that were injected with saline for control. Also for control, the group administered with mitomycin was isolated. The experiment lasted 30 days, for each group the average survival time in days was determined, in addition, the number of individuals that survived by the end of the 30-day period was determined. The mice were weighed before the experiment and after 6 days. Weight change was measured as a measure of toxicity. A total weight of 20 g was investigated. Weight loss of approximately 2 g was considered insignificant. The results were expressed as T / C, which is the ratio of the average survival time of the treated mice to the average survival time of the saline-treated mice. As a rule, the mice treated with the solution died within 9 days. The expression maximum effect in Table 1 means at what value of a given dose the value of T / C takes place. The numbers in parentheses in Tables 1–4 refer to mitomycin C, taken for control in the same series, which makes it possible to establish the relative activity of the proposed compounds relative to mitomycin C. The minimum effect in terms of% T / C was considered to be 125. The minimum effective the dose given in Table 1 is the dose leading to a T / C value of about 125. The two values given in Table 1 in the Average weight change one after another correspond to the average weight loss of the mouse at the maximum effective dose and at the minimum effective dose.
    0
    five
    0
    five
    0
    five
    Table 2 contains the results of anticancer tests in B16 melanoma in mice. BDFy mice were subcutaneously implanted with a tumor. The experiment lasted 60 days. Each dosage was tested on a group of ten mice for which the average survival time was determined. Control animals infected at the same time, which were injected with a carrier-free drug, showed an average survival time of 24 days. The survival time relative to the survival time of the control animals (t / s) was used to determine the efficiency, the maximum and minimum effective doses were determined for each test compound. Minimum effective dose T / C 125 o For each dosage level, the test animals were injected with medication on the 1st, 5th and 9th day.
    Table 3 contains additional results of antitumor excretions in BDFy mice with B1b melanoma infected intraperitoneally. tumor (0.5 ml of 10%). The experiment lasted 60 days. Each dosage was tested on a group of ten min- utes; the average survival time was determined for each group. Control animals infected at the same time as the subjects who were injected with the vehicle without the drug showed an average survival time of 20.5 days. Survival times with respect to controls (t / s) were used to determine efficacy, dp of each test compound was determined by the maximum and minimum effective doses. The maximally effective dose corresponded to the value of% T / C 125. Each dosage of the test compound was administered intraperitoneally on the 1st, 5th, and 9th day.
    Table 4 shows the results of the suppressive effect on the spinal cord of the compounds of Examples 1, 3 and 13 when administered intravenously to mice compared with mitomycin. Myaam was administered a single dose of the test compound.
    On the day of O, and on the days of O, 4 and 7, the full count of Leyko was 1: 1 1 t. Numbers. for days 4 and 7, are shown in Table 44 as the percent change (j%). Other calculations were made on days 0 and 4, and recorded as a percentage difference (4%) on day 4. As shown in the table, 4 groups of 10 animals were given different doses of the tested compounds. The values of ii, given in parentheses, correspond to the comparative values for mitomycin C. It was concluded that the compounds according to examples 1,3 and 13 in smaller stele suppress the activity of the spinal cord than mitomycin C, at doses with equal mortality, these compounds show significantly less effect on neutrophil counting than mitomycin C.
    Form m u la izobre te n i
    g. Method for the preparation of 7-acylamino-9a methoxymitosan of the general formula
    ABOUT
    thirty
    CHzOCNHg OSS
    Nri
    where R is hydrogen or methyl
    Rj is a group of KESO -, R NHCO-,, () jPS or, j-, where Rj is hydrogen, lower alkyl, unsubstituted or substituted by fluorine or chlorine, phenyl, benzyl or cyclohexyl, R4 is lower alkyl or benzyl,
    characterized in that 1-1.5 mol of sodium hydride acts on mitomycin C in a solution of dimethylformamide, followed by treatment of the anionic form of mitomycin C formed in this way, 1-2 mol.h. the corresponding acylating agent at -30 to +25 C in dimethylformamide.
    1228 (195) 2 (4), 6; +0.2
    220 (220) 2 (4) 0.5-2.8; -1,1
    3186 (195) 1 (4), 6; +0.6:
    13
    Uba / ZU14
    Table 3
    权利要求:
    Claims (1)
    [1]
    Formula of the invention: Method for the preparation of 7-acylamino-9-methoxymitosan of the general formula
    O O II
    A CH 2 OCNH 2 DOS 3
    CHS II Y
    O * - where R, - hydrogen or methyl Rj - groups R 3 CO -, R 3 NHCO-,
    R 4 OCO-, (R 4 O) jPS or R 3 SO 7 ~, where R 3 is hydrogen, lower alkyl, unsubstituted or substituted by fluorine or chlorine, phenyl, benzyl or cyclohexyl, R 4 is lower alkyl or benzyl, characterized in that mitomycin C in a solution of dimethylformamide is 1-1.5 mol.h. sodium hydride with subsequent processing of the resulting anionic form of mitomycin C 1-2 mol.h. the corresponding acylating agent at a temperature of -30 to + 25 ° C in dimethylformamide.
    Table and 1 Connection example Maximum effect Minimum effect at a dose, mg / kg Average change T / S,% Dose mg / kg certain weights, g 1 183 (144) *** 3.2 (3.2) *** 1.6 -2.1, -1.3 244 (228) 6.4 (4.8) <0.4 -2.2, +0.3 2 183 (228) 6.4 (4.8) 0.8 -1.0 +0.5 6 183 (228) 12.8 (4.8) 0.8 -0.8, +0.4 5 219 (263) 25.6 (4.8) 0.8 -2.8, -1.3 3 233 (228) 6.4 (3.2) 0.2 -1.4, +0.3 thirteen 250 (228) 12.8 (3.2) 0.2 -1.8, +0.4 14(BL-6938) 163 (363) 3.2 (4.8) <0.2 -0.6, +0.6 eleven 200 (244) 6.4 (4.8) <0.2 -2.2, -1.4 10 189 (356) 6.4 (4.8) <0.2 -1.2, -0.3 7 213 (313) 3.2 (3.2) <0.1 -0.3 +0.6 9 206 (313) 3.2 (3.2) <0.025 -1.8, +2.3 fifteen inactive 8 229 (241) 3.2 (4.8) <0.2 -1.6, -0.9
    T a b l 2 Connection example . - ηMaximum effect The minimum. effective dose, mg / kg The average weight loss per day, g t / s,% Dose mg / kg 1 228 (195) 2 (4) <1 -0.6; +0.2 220 (220) 2 (4) ’<0.5 -2.8; -1.1 3 186 (195) 1 (4) <1 +0.6; +0.6:
    1364/39
    thirteen ·
    Table 3 Connection example Maximum effect The minimum effective dose, mg / kg Average weight loss per day, g T / S,% Dose mg / kg 3 249 (173) 4 (2) <0.5 -0.4 no thirteen 173 (173) 1.5 (2) <1.5 No no 16 270 (202) 7 (3) <7 +1.2; 1,2
    Table 4
    Connection example Iv dose, mg / kg Day 4 ----.------- 1Day 7WBCHK,Δ% Deathby the 14thday IVSPK,% Δ b The number of neutrophils, &% White blood cell count, Δ7 „ 3 12.8 -69 - - 5/5 fatal outcome 5/5 6.4 -57 (-82) -5 (-96) -65 (-80) -15 (-58) 1/10 3.2 -26 (-54) +11 (-62) -30 (-53) -18 (-16) 0/10 1 12.8 -83 5/5 fatal outcome 5/5 6.4 -77 (-71) 10/10 Death 10/10 3.2 -62 (-43) -25 (-77) -69 (-35) -22 (-8) 6/10 thirteen 12.8 -64 +6 -78 -14 10/10 6.4 -26 (-78) -2 (-96) -31 (-75) +18 (-57) 0/10
    Compiled by I. Bocharova Editor M. Tsitkina Tehred L. Serdyukova Proofreader V. Butyaga
    Order 6387/58 Circulation 372 Subscription
    VNIIIPI of the USSR State Committee for Inventions and Discoveries 113035, Moscow, Zh-35, Raushskaya embankment, d. 4/5
    Production and printing company, Uzhhorod, st. Project, 4
    类似技术:
    公开号 | 公开日 | 专利标题
    KR101576159B1|2015-12-09|Heteroalkyl linked pyrimidine derivatives
    SU1364239A3|1987-12-30|Method of obtaining 7-acylamino-9a-methoxymytozan
    CN104910161B|2018-03-30|Pyrazolopyrimidine compound and method as JAK inhibitor
    EA035816B1|2020-08-14|Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
    CA2916097A1|2014-12-24|Substituted benzylpyrazoles
    CN102333779A|2012-01-25|Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
    AU2009255042A1|2009-12-10|Alpha helix mimetics and methods relating thereto
    AU2015370911B2|2020-07-09|Inhibitors of Akt kinase
    CN112189008A|2021-01-05|Modulators of integrated stress pathways
    US20120178754A1|2012-07-12|Furazano &#39;3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents
    WO2019132561A1|2019-07-04|Amino-methyl piperidine derivative as kinase inhibitor
    EP0194464B1|1991-04-03|Amino acid derivatives and use thereof for the preparation of an anticonvulsant
    CN110461836B|2020-10-20|Selective kinase inhibition compound and application thereof
    KR100372632B1|2003-05-12|Anticancer 2-aminocarbonyl-1,2-bis | -1- | hydrazine
    JP2019535658A|2019-12-12|Pharmaceutical compounds
    EP2890677B1|2017-11-15|N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
    SU1436881A3|1988-11-07|Method of producing 7-aminosubstituted-9a-methoxymitozane
    HU9601976A2|1997-09-29|4-fluoralkyl benzoylguanidines, process for producing them and pharmaceutical compositions containing these compounds
    WO2013119499A1|2013-08-15|Novel compounds for the treatment of hepatitis c
    CN108864114B|2020-11-06|Selectivity A2AReceptor antagonists
    TW202110838A|2021-03-16|Novel compounds for inhibition of janus kinase 1
    PL125177B1|1983-04-30|Process for preparing derivatives of salts of sulfonic acid with alkali metal and sulfonamid derivatives of 6,6&#39;-methylene-bis-/2,2,4-trimethyl-1,2-dihydroquinoline
    WO2021169913A1|2021-09-02|Pde4 inhibitor compound and medical use thereof
    EP3915989A1|2021-12-01|Jak inhibitor and preparation method therefor
    IE851698L|1986-01-06|Oxaazaphosphorine derivatives
    同族专利:
    公开号 | 公开日
    YU45688B|1992-07-20|
    FI845037L|1985-06-24|
    NO845100L|1985-06-24|
    NO163570B|1990-03-12|
    PT79741A|1985-01-01|
    IL73876A|1991-08-16|
    AU3571084A|1985-06-27|
    HUT37434A|1985-12-28|
    AT386828B|1988-10-25|
    PT79741B|1987-01-16|
    KR850004762A|1985-07-27|
    SE8406577D0|1984-12-21|
    DK621484D0|1984-12-21|
    HU193245B|1987-08-28|
    SE8406577L|1985-06-24|
    US4642352A|1987-02-10|
    IE57835B1|1993-04-21|
    FI845037A0|1984-12-19|
    IE843318L|1985-06-23|
    NZ210254A|1988-02-29|
    IL73876D0|1985-03-31|
    DK169477B1|1994-11-07|
    KR910009329B1|1991-11-11|
    ZA849907B|1985-08-28|
    LU85711A1|1985-09-12|
    GB2151627A|1985-07-24|
    NO163570C|1990-06-20|
    GB2151627B|1988-03-30|
    FR2557112B1|1987-02-13|
    DE3447003A1|1985-07-04|
    JPS60169481A|1985-09-02|
    OA07911A|1986-11-20|
    NL8403852A|1985-07-16|
    IT1178792B|1987-09-16|
    GB8432513D0|1985-02-06|
    GR82567B|1985-04-23|
    FI81099B|1990-05-31|
    AU561376B2|1987-05-07|
    ES538804A0|1985-12-16|
    JPH0471076B2|1992-11-12|
    DE3447003C2|1994-11-17|
    YU215284A|1990-06-30|
    CH665641A5|1988-05-31|
    DD228259A5|1985-10-09|
    ATA407484A|1988-03-15|
    MY100976A|1991-06-15|
    IT8424227D0|1984-12-21|
    DK621484A|1985-06-24|
    ES8603485A1|1985-12-16|
    AR244231A1|1993-10-29|
    CA1239645A|1988-07-26|
    FI81099C|1990-09-10|
    BE901377A|1985-06-21|
    FR2557112A1|1985-06-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    BE655399A|
    US27384A|1860-03-06|Slide-valve for steam-engines |
    CA771155A|1967-11-07|Kyowa Hakko Kogyo Co.|Phosphorus-containing derivatives of mitomycin c|
    US3660578A|1957-04-06|1972-05-02|Kyowa Hakko Kogyo Kk|Mitomycin c|
    NL129868C|1963-06-07|
    DE1570029A1|1964-07-09|1970-04-09|Kyowa Hakko Kogyo Kk|Process for the production of mitosan compounds|
    US3420846A|1964-08-25|1969-01-07|Kyowa Hakko Kogyo Kk|7-substituted mitomycin a|
    US3332944A|1964-11-02|1967-07-25|American Cyanamid Co|Antibiotic derivatives of mitomycins a, b, c and porfiromycin|
    FR1540921A|1965-05-18|1968-10-04|Kyowa Hakko Kogyo Kk|Process for the preparation of thiourea derivatives of mitomycin c|
    US3410867A|1965-11-22|1968-11-12|Kyowa Hakko Kogyo Kk|Mitomycin derivatives|
    JPS61834B2|1977-08-31|1986-01-11|Kyowa Hakko Kogyo Kk|
    EP0008021B1|1978-07-18|1984-05-16|Kyowa Hakko Kogyo Co., Ltd|New mitomycins and processes for production thereof|
    US4268676A|1979-12-05|1981-05-19|University Patents, Inc.|Mitomycin analogs|
    US4444768A|1980-03-04|1984-04-24|Ciba-Geigy Corporation|Pyrimido[1,6-a]indoles, pharmaceutical preparations containing them, and methods of treating pain and inflammation with them|
    NZ199617A|1981-05-15|1985-08-30|University Patents Inc|Azirinopyrroloindole-4,7-dione derivatives and pharmaceutical compositions|
    JPS58201791A|1982-05-19|1983-11-24|Katsuo Unno|Hematoporphyrin derivative|
    US4487769A|1982-06-04|1984-12-11|Bristol-Myers Company|Amidines|US4487769A|1982-06-04|1984-12-11|Bristol-Myers Company|Amidines|
    NZ206932A|1983-02-07|1987-08-31|University Patents Inc|Certain 6- mitosanes and pharmaceutical compositions|
    US4803212A|1983-04-11|1989-02-07|Bristol-Myers Company|Amino disulfides|
    FR2571373A1|1984-10-09|1986-04-11|Bristol Myers Co|PROCESS FOR PREPARING N7-SUBSTITUTED MITOMYCIN C DERIVATIVES|
    CA1282069C|1985-09-12|1991-03-26|Damon L. Meyer|Antibody complexes of hapten-modified diagnostic or therapeutic agents|
    JPS6354380A|1986-08-26|1988-03-08|Kyowa Hakko Kogyo Co Ltd|Mitomycin derivative|
    ZA886812B|1987-11-23|1989-07-26|Bristol Myers Co|Anti-tumor prodrugs|
    US4874779A|1988-06-29|1989-10-17|Bristol-Myers Company|Mitomycin phosphate derivatives|
    US5214804A|1992-01-27|1993-06-01|Carey Michael J|Protective mask with scarf|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/564,806|US4642352A|1983-12-23|1983-12-23|Acylamino mitosanes|
    [返回顶部]